Anteris Technologies Global
AVR | NASDAQ
$5.70
+$0.28 (+5.17%)
At close: Nov 16, 2026, 4:00 PM ET
$5.68
-$0.02 (-0.35%)
After-hours:
Nov 16, 2026, 6:33 PM ET
Anteris Technologies Global Company Profile
Company profile explainedCompany Profile
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Key Executives
| Name | Position |
|---|---|
| Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer |
| Brent A. Moen | Chief Financial Officer |
| Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board |
| David Denis | President & Director |
| Matthew McDonnell | Head of Australia |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | PRE 14A | Filing |
| Oct 08, 2026 | 4 | Filing |
| Oct 06, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
| Sep 24, 2026 | 424B3 | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 21, 2026 | 424B3 | Filing |
| Sep 17, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 3 | Filing |
Anteris Technologies Global
| Country | United States |
| IPO Date | Dec 13, 2024 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 174 |
| CEO | Wayne Geoffrey Paterson |
Contact Details
860 Blue Gentian Road, Suite 340 Eagan,
Minnesota 55121 United States
Stock Details
| Ticker Symbol | AVR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002011514 |
| CUSIP Number | 03675P102 |
| ISIN Number | US03675P1021 |
| SIC Code | 3842 |
Add to Watchlist
Select watchlists to add or remove AVR